Overview
Angiodysplasia of the stomach refers to abnormal blood vessel formations that can lead to chronic bleeding, often resulting in iron deficiency anemia requiring frequent transfusions despite endoscopic interventions 1.Diagnosis
Endoscopic identification of characteristic vascular malformations 1.
Imaging studies (e.g., angiography) may be used to confirm diagnosis and assess extent 1.
Laboratory findings typically include iron deficiency anemia and sometimes iron deficiency without overt bleeding 1.Management
First-line: Endoscopic therapy (e.g., thermal coagulation, sclerotherapy) 1.
Adjunctive:
- Octreotide long-acting release (40 mg intramuscular every 28 days) may reduce transfusion requirements 1.
- Standard care includes continued endoscopic management and supportive treatments like iron supplementation 1.Special Populations
Elderly: Management principles similar to general population, with emphasis on minimizing procedural risks 1.
Comorbidities: No specific recommendations provided; focus on managing underlying conditions and bleeding control 1.Key Recommendations
For patients with angiodysplasia-related anemia requiring frequent transfusions, consider octreotide long-acting release (40 mg every 28 days) to potentially reduce transfusion needs (Evidence: Moderate) 1.
Primary management should include endoscopic interventions aimed at controlling bleeding sources (Evidence: Strong) 1.
Regular monitoring and supportive care, including iron supplementation, are essential adjuncts to bleeding control strategies (Evidence: Expert opinion) 1.References
1 Goltstein LCMJ, Grooteman KV, Bernts LHP, Scheffer RCH, Laheij RJF, Gilissen LPL et al.. Standard of Care Versus Octreotide in Angiodysplasia-Related Bleeding (the OCEAN Study): A Multicenter Randomized Controlled Trial. Gastroenterology 2024. link